Answers are grounded in this paper and cite their sources.
Venetoclax plus anti-CD20 monoclonal antibody (mAb) regimens have revolutionised treatment for chronic lymphocytic leukaemia (CLL); however, CD20 antigen loss is a potential consequence. Given emerging roles for re-treatment with venetoclax plus anti-CD20 mAb and CD20-targeting bispecific antibodies in CLL, we retrospectively assessed the prevalence of CD20-negative CLL in patients treated with fixed-duration venetoclax/obinutuzumab (Ven-O) or venetoclax/rituximab (Ven-R). CD20 expression was assessed by flow cytometry at baseline, end of treatment (EOT) and disease progression, with negativity defined if the log difference in median fluorescence intensity (MFI) between CLL cells and T-cell controls was less than 0.5. Of 60 patients, (34 Ven-O, 26 Ven-R), 6 demonstrated pre-therapy CD20 negativity (1 treatment-naïve, 5 pre-treated) and 10/29 (34%) with measurable residual disease (MRD) at EOT demonstrated post-therapy CD20 loss (4 Ven-O, 6 Ven-R). Notch receptor 1 (NOTCH1) variants were identified in 5/10 (50%) patients with CD20-negative MRD, compared to 3/18 (17%) with CD20-positive MRD and 6/29 (21%) with undetectable MRD. Five patients had longitudinal assessment, with all demonstrating persistent CD20-negative disease long after antibody exposure (follow-up 12-39 months). These results have potential implications for future treatment selection and efficacy.
No takes yet. Share an insight, caveat, or question.
Stewart et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: